Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rivastigmine in Parkinson's disease dementia: profile report.

Literature DB >> 17362052

Rivastigmine in Parkinson's disease dementia: profile report.

M Asif A Siddiqui¹, Antona J Wagstaff.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2007 PMID： 17362052 DOI： 10.2165/00002512-200724030-00006

Source DB: PubMed Journal: Drugs Aging ISSN： 1170-229X Impact factor: 3.923

× No keyword cloud information.

26 in total

Review 1. Treatment interventions for Parkinson's disease: an evidence based assessment.

Authors: Olivier Rascol; Christopher Goetz; William Koller; Werner Poewe; Cristina Sampaio
Journal: Lancet Date: 2002-05-04 Impact factor: 79.321

2. Risk of dementia in Parkinson's disease: a community-based, prospective study.

Authors: D Aarsland; K Andersen; J P Larsen; A Lolk; H Nielsen; P Kragh-Sørensen
Journal: Neurology Date: 2001-03-27 Impact factor: 9.910

Review 3. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

Authors: Dag Aarsland; Urs P Mosimann; Ian G McKeith
Journal: J Geriatr Psychiatry Neurol Date: 2004-09 Impact factor: 2.680

4. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.

Authors: C Ballard; R Lane; P Barone; R Ferrara; S Tekin
Journal: Int J Clin Pract Date: 2006-06 Impact factor: 2.503

Review 5. A systematic review of prevalence studies of dementia in Parkinson's disease.

Authors: Dag Aarsland; Julia Zaccai; Carol Brayne
Journal: Mov Disord Date: 2005-10 Impact factor: 10.338

6. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.

Authors: Nigel H Greig; Tadanobu Utsuki; Donald K Ingram; Yue Wang; Giancarlo Pepeu; Carla Scali; Qian-Sheng Yu; Jacek Mamczarz; Harold W Holloway; Tony Giordano; DeMao Chen; Katsutoshi Furukawa; Kumar Sambamurti; Arnold Brossi; Debomoy K Lahiri
Journal: Proc Natl Acad Sci U S A Date: 2005-11-07 Impact factor: 11.205

7. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.

Authors: Werner Poewe; Erik Wolters; Murat Emre; Marco Onofrj; Chuanchieh Hsu; Sibel Tekin; Roger Lane
Journal: Mov Disord Date: 2006-04 Impact factor: 10.338

8. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

Authors: Nicolaas I Bohnen; Daniel I Kaufer; Larry S Ivanco; Brian Lopresti; Robert A Koeppe; James G Davis; Chester A Mathis; Robert Y Moore; Steven T DeKosky
Journal: Arch Neurol Date: 2003-12